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Glioblastoma tumor. Photograph by Sydney S Schochet, MD. MedPix.

B

rain cancer: two words
you never want to hear
together. Even with all
of the different kinds of cancer,
brain cancers represent some of
the deadliest cancers known to
humanity, with an average 5-year
survival rate of only 36%.1 There
are many different subtypes within
brain cancer, but one of the most
famous subtypes is glioblastoma
multiforme (GBM). Although you
may not have heard of it by that
particular name, this cancer gained
notoriety in 2018, as it is the cancer
that claimed the life of the former
United States Senator John McCain.
GBM is the most commonly
occurring primary malignant brain
tumor, accounting for 80% of all
primary brain tumors and 60% of all
brain tumors.2 It is also known for
being one of the most lethal and
aggressive forms of brain cancer,
with only 5.5% of patients surviving
more than 5 years from the time
of diagnosis.3 Still, there may be
a glimmer of hope. Researchers
have found that cancer patients
who contracted certain viruses
actually had increased survival.
Even some of the deadliest viruses
in the world have shown potential
to help increase survival in patients
that contracted them. Could our
villains of yesterday be our saviors
of tomorrow? Could it be that the
enemy of my enemy is my friend?

Consequences of
Glioblastoma
Although the poor survival
rate of GBM is enough to
darken anyone’s day, the disease
unfortunately comes with even
more problems. Most, if not all,
patients who somehow survive the
disease are subject to debilitations
that cripple them for life. Most
long-term survivors of GBM have
reported to suffer from crippling
fatigue, which severely affected
their quality of life. For adult
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long-term GBM survivors, many
faced physical, psychological, and
cognitive declines. Survivors suffer
from impaired motor function, both
in respect to coordination and
speed. Also, sustained attention
and the ability to maintain
meaningful social relationships are
found to be reduced in long-term
surviving adults. For long-term
GBM survivors that were children,
there were very few of these
negative effects. They displayed
few, if any, cognitive deficiencies.
Researchers believe that when
the GBM tumor subsides more
quickly, many of these negative
impairments are avoided. There has
been little evidence to suggest that
a correlation exists between these
effects and tumor location, leading
researchers to believe that these
consequences can arise regardless
of the tumor location.4
Other than the direct effects
of the tumor itself, patients
also experience psychological
problems from the knowledge of
simply having a tumor residing
in their brains. When notified
about the length of treatment and
the uncertainty of the treatment
even working, patients frequently
experience a downward trend in
overall mood. The financial burden
of the disease also affects the
mental health of GBM patients
significantly. This is considered
exceptionally prevalent for GBM
cases in Western countries, such
as the United States, where social
support for medical illnesses
by friends and family is not as
consistent as in countries like
India, based on societal reactions
to terminal diseases. Culturally in
the United States, there is less of a
desire for broader social networks,
like friends and family, to constantly
be in contact with patients who are
in the hospital. In other places, it is
more common for a wider range of
friends and family to be invested in
the health of the patient.

John McCain’s official portrait. Public Domain.

There is also evidence to
show that depression and GBM
are linked directly to one another.
Although psychological reasons
for depression are prevalent,
there are also mechanisms for
the manifestation of depression
based on the progression of
GBM. Historically, the increase
in depressive behaviors in GBM
patients had been overlooked, as
the depression of GBM patients
seemed logical simply because
it is a stressful disease.5 Yet,
depressive behaviors were found
in GBM patients even prior to the
patient learning of their diagnosis,
suggesting that the emergence
of both diseases are connected.
Although there are many different
ways that depression is caused
in cancer patients, GBM is known
mainly to cause depression by
limiting the amount of serotonin
in the brain. There are a variety
of neurotransmitters—molecules
that can induce responses in
neural cells—and serotonin is the
neurotransmitter that is essential for
happiness and stabilizing the mood
of healthy individuals. Serotonin
30
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is also implicated in regulating
sleep and hunger. It seems clear
that having reduced serotonin
in the brain would have serious
consequences on the well-being of
an individual, and GBM does just
that. This is because GBM cells have
increased activity of an enzyme
called IDO.6 IDO is responsible for
converting tryptophan, a protein
amino acid, into a molecule called
kynurenine. This is problematic for
one reason: tryptophan is also the
precursor for serotonin. When IDO
is highly active, like it is in GBM,
there is not as much tryptophan
available to be converted into
serotonin, leading to a reduction in
the serotonin produced.
To better illustrate the cause
and effect of GBM causing

depression, we will consider a pipe.
Tryptophan is being put in one
end of the pipe, and serotonin is
coming out of the other side. When
there is about as much serotonin
coming out as the tryptophan that
you are putting in, you are happy
that there is sufficient serotonin
being made and all is well. The
increased IDO activity is like if
there was a leak in that pipe, and
some of the tryptophan you put in
the pipe does not make it to the
other side as serotonin. Instead,
it is lost as something else (Figure
1). This reduced serotonin leads
to unstable mood and depression.
Depression has also been linked
to significant decreases in GBM
survival, so physicians must try to
combat the two diseases at once.7

The Fight Against
Glioblastoma
The poor prognosis of GBM
does not reflect the amount of time
and money put into researching
therapies for it. Researchers have
tried for many years to develop
new therapies with the hope of
improving the survival of patients
diagnosed with GBM, yet they have
had little success.8 Currently, the
standard of care treatment involves
a combination of chemotherapy,
surgery, and radiotherapy. In most
cases, surgeons cut out as much
of the tumor from the brain as
possible before using radiation
to try and kill off any remaining
cancerous tissue. The patient is

Figure 1. Mechanism of depression in GBM patients. A) Healthy individuals do not have the IDO “leak,” and therefore can produce sufficient amounts of
serotonin. The sufficient amounts of serotonin are enough to keep the individual happy and stable. B) GBM patients have increased activity of the IDO
enzyme/leak, which causes some of the tryptophan to not be converted into serotonin. The insufficient production of serotonin causes depression in
GBM patients. (Created with BioRender.com. Figure by Kai Wilczewski-Shirai, licensed under CC BY-NC-ND 4.0.)
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then usually given a regimen of
drugs to take in an attempt to
stop the tumor from growing back.
This approach has a multitude of
problems. One of the reasons GBM
is so deadly is because the tumor
penetrates deep into healthy brain
tissue, making it difficult to remove
significant amounts of the tumor
without doing significant damage
to the rest of the brain. In fact,
relapse occurs in 80% of patients
after attempts to surgically remove
the cancer, where the new tumor is
found within 2 cm of the original.
Radiation is also problematic since
it indiscriminately destroys tissue,
affecting healthy brain tissue as
well as cancerous brain tissue.3
In addition to surgical removal
and
radiation,
chemotherapy
also comes with its fair share of
limitations. Many drugs that can be
used for other cancers are found to
not be as effective in treating GBM.
This is partially due to the bloodbrain barrier (BBB), which prevents
many drugs from reaching the
target tumor in the brain. As the
BBB prevents a large proportion
of a drug dose from entering the
brain, it is necessary to administer
a high dosage so that an adequate
amount of drug can reach the
tumor. Otherwise, the drug may
be ineffective against the brain
tumor. However, these very high
doses tend to be intolerable for the
patient’s body as a whole, causing
harm in other areas of tissue. The
most frequently used drug in
chemotherapy is temozolomide,
which damages the DNA in cancer
cells, thus reducing their viability.
This drug has still been found to
be insufficient because many GBM
cells express a protein called AGT,
which can repair the DNA damage
done by temozolomide.3
The current approach to
treat GBM is a long and painful
process by which the cognitive
consequences are worsened, since
treatment damages healthy brain

Glioblastoma cells transfected with green fluorescent protein in culture. Image by Alex Gray. Cell
Image Library doi:10.7295/W9CIL38961

tissue as well. To avoid long-term
impairments in quality of life, it
has been clear for some time that
different treatment approaches are
needed.

Viruses as Potential
Therapy
The idea of using viruses as
cancer therapies is not new to the
medical world. While the use of
viruses to treat cancer may sound
like a crazy idea, the logic and
evidence behind it is sound. In
the early twentieth century, a viral
outbreak in a cancer ward led to
an unprecedented increase in the
health and survival of those cancer
patients.9 Later, using data from the
World Health Organization from
1955-2008, it was discovered that
individuals with cancer who were
also infected with the malaria virus
had greater survival compared to
their counterparts who did not
have malaria.10 Intrigued by this

phenomenon, researchers began
to suspect that something about
viruses helped the body fight off
cancer, perhaps by eliciting an
immune response in the body. The
researchers weren’t wrong, but
they were far from uncovering the
full picture. After years of greater
examination, it was discovered
that viruses did indeed elicit an
immune response, but were also
the agent directly responsible for
the destruction of cancer cells.
As viruses have evolved over
millions of years, they have gained
the ability to target specific types
of cells while leaving most, if not
all, other cells unaffected. Taking
advantage of this natural selectivity
has given researchers an exciting
new way to make safe therapies for
a variety of diseases.11 As there are
many different types of viruses that
only affect certain tissues, there are
many different types of cancers that
have the potential to be treated
this way.
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patients’ health within a month.
This means that many individuals
afflicted with GBM could be spared
from the cognitive and physical
after-effects of GBM by using viral
therapies.13

How Are Viruses
Engineered to Attack
Only Cancer Cells?

Figure 2. Common strategies for how viruses can be made to affect only cancer cells. A) The transductional targeting strategy involves using/making a virus that can only infect cancer cells due to
having ligands that only interact with specific cell surface receptors. If the ligands on the virus correspond to the receptors, then the virus can infect the cell. If the ligands do not correspond to the cell
surface receptors, then the virus cannot infect and harm the cell. B) The non-transductional targeting
strategy involves giving viruses specific proteins and machinery, so that they can only replicate inside
certain cells. In a healthy cell, the infection leads to an unharmed cell. In cancer cells, the virus can
replicate and eventually lead to cell lysis, which releases more viral particles to kill more cancer cells.
Original image by Kai Wilczewski-Shirai. Created in BioRender.

The specificities of viruses can
overcome many of the obstacles
that prevent most other therapies
from being effective. As viruses
can destroy specific cells while
unharming other cells; they can
exclusively
destroy
cancerous
cells that penetrate deep into
healthy tissue. The same specificity
also eliminates the need for an
abundance of therapeutic agents
in order to reach the target tumor.12
33

Viruses can multiply by destroying
target cells, so a single viral particle
can be sufficient to start the
treatment of entire tumors. This is
because once the virus multiplies, it
can destroy even more cells, much
like a domino effect.
In comparison to the previous
methods of treating cancer, viral
therapies have been found to be
fairly fast acting, with significant
improvements occurring to the

Although there are viruses that
have been found to naturally attack
cancer cells, most of the time
researchers must engineer viruses to
ensure the harm of only the cancer
cells. There are two main strategies
that researchers use to achieve
this. The most common approach
is called transductional targeting.
Viruses have components that
bind to specific receptor proteins,
which are located on the surface of
cells, called ligands. These ligands
can only bind to certain receptors,
and if a virus cannot bind to these
receptors, they cannot enter or
infect the cell.14 Therefore, by
engineering viruses to have ligands
that only bind to receptors found
on cancer cells and not healthy
cells, researchers can make viruses
that do not harm healthy tissue
(Figure 2A). To further explain this
idea, imagine that the virus is a
person with a key and that all of
the cells are locked houses. The
person cannot enter all of the
houses because they don’t have
the correct key for each house, but
the person can enter the house with
the corresponding key. The ligands
of the virus act like this key, and so
researchers can make viruses target
certain cells by only giving them
the “keys” to certain houses/cells.
The second strategy is called
non-transductional targeting. This
strategy involves giving viruses
special molecular proteins that are
needed for the virus to replicate
once they enter the cell. The virus
is allowed to infect cells freely,
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but the proteins these viruses
have determine which cells will
be harmed. These proteins can
only be used inside specific cells,
exclusively allowing the virus to
replicate inside and kill those cells.
If the virus is inside a targeted cell,
like a cancer cell, the proteins in
the virus will allow it to replicate.14
Then, the cell will lyse, or break
open, releasing the replicated viral
particles and allowing them to infect
additional cells.15 Cells that are not
compatible for the replication of
the virus can be infected, but are
ultimately unharmed (Figure 2B).
To better understand this, let’s go
back to the house metaphor, except
in this case let’s imagine that the
people/viruses are burglars. The
burglars can get into all the houses,
but while they are in the house,
they encounter a security system.
Depending on the equipment
they brought with them, they can
either continue the burglary or
they are stopped by the security
system. The specialized equipment
can only work on certain security
systems. Researchers can give the
viruses/burglars special proteins/
equipment that will allow them to
kill/burgle certain cells/houses.
It is common for researchers
to employ both of these strategies
at the same time. By engineering
the virus to only infect certain cells

and to only replicate inside certain
cells, we can be even more sure
that the virus will selectively kill just
the targeted cells. In this way, even
the deadliest viruses can be turned
into safe and powerful therapeutics
to treat brain cancer.

Cases of Success
As of today, there has only
been one viral therapy approved
by the FDA to treat cancer, which
is a modification of the herpes
simplex virus to treat melanoma, or
skin cancer. Regardless, there has
recently been a lot of promise in
the use of viruses to treat GBM.16
One of the most well-known cases
of this is the use of Zika to kill GBM
cells. This virus, which causes birth
defects, Zika fever, and Guillain–
Barré syndrome, has shown
promise as a potential therapy for
GBM.17 There are studies showing
that Zika only infects GBM cells
when added to a dish containing
both GBM cells and healthy neural
cells.18 Although Zika has not gone
through the rigorous clinical trial
process that would allow it to be
approved for widespread use, the
preclinical results point strongly to
the safety and efficacy of the virus
as a tumor-busting therapeutic. At
the very least, Zika has been shown
to make cancer cells more sensitive

to a variety of other cancer drugs,
meaning that safer, smaller drug
doses can be used to treat GBM
when used with Zika.
In addition to Zika, Newcastle
disease virus, a contagious viral
disease known to mainly affect
birds, has also been found to have
some success in treating GBM.
Although Newcastle disease virus is
an avian disease, it is known to be
able to affect humans and cause a
mild fever, although almost all cases
in humans are asymptomatic.19 In
1999, researchers attempted to use
a strain of Newcastle disease virus
developed in 1968 to infect cancer
patients. Researchers used the nontransductional targeting strategy
for this virus, using a protein called
interleukin 2 to limit the replication
of the virus to only within cancer
cells.20 They found that the patients’
tumors shrank while normal cells
remained unaffected. This story of
success led researchers to try using
Newcastle disease virus in GBM.
In a study published in 2020, four
different patients diagnosed with
GBM were infected with the virus.
Three of the four patients in this
study are still alive today, with one
patient still surviving 15 years after
diagnosis (Figure 3). Not only did
this patient surpass the typical time
frame of five years after diagnosis
that usually only has a 5.5% chance

Figure 3. A GBM tumor shrinking from Newcastle disease virus therapy. The white area inside the yellow circle represents the tumor. (Adapted from
Gesundheit, B. et al. (2020). Frontiers in Oncology, licensed under CC BY 4.0)
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of survival, the patient lived three
times as long as previously seen.
Diagnosed at 33 years of age, this
woman had suddenly lost her ability
to speak and lost motor function in
her left arm. She was treated with
all the conventional therapies, but
they were relatively ineffective.
However, after receiving viral
therapy she regained her speech
and motor function, and later went
on to give birth to a healthy baby.
She currently lives almost as if she
never had GBM in the first place.
Stories of stability and happiness
are also true for the other two
surviving patients, who have been
reported as enjoying a normal
quality of life.21
The patient who did not
survive lived 6 years after diagnosis,
which is amongst the highest
percentiles for survival time, and
the patient passed away after one
year of stopping the therapy. Brain
imaging showed that the tumors of
the patient shrank at an incredible
rate while being treated with the
virus, while the rest of the brain
remained unaffected.
Another virus that has been
used to treat GBM is poliovirus.
Poliovirus is commonly known
as the virus that causes polio,
which infects motor neurons and
alters the central nervous system,
resulting in muscle weakness and
paralysis. Previous research has
found that GBM cells overexpress
the poliovirus receptor CD155,
and poliovirus preferentially infects
GBM cells because of this. In a study
published in the New England
Journal of Medicine, researchers
infected 61 patients with an
engineered strain of poliovirus.
The patients experienced a 2-3
year increase in survival from the
national average of less than a
year.22,23 All over the world, massive
clinical trials are underway using an
engineered poliovirus. Dr. Curry,
who is the primary investigator of
a poliovirus-GBM clinical trial at
35

the Mass General Cancer Center,
has stated that the early data
gives much reason to be hopeful,
and that he is optimistic that this
will become an effective way to
improve the outcome for those
diagnosed with GBM.24

Why Aren’t Viral
Therapies More
Common?
Nobody would blame you for
asking why these therapies are not
more common when they seem
like medical miracles. Other than
the difficulty for developing these
viral therapies, there is significant
public push back. As they do
involve viruses, people fear that if
these therapies are not properly
contained, they will pose a public
health threat. With the public’s
view of viruses primarily being
one of fear, especially due to the
COVID-19 pandemic, people are
reluctant to trust viruses. This fear
is especially bad for viruses like
Zika or poliovirus, as they have also
been viewed as especially harmful
in our lifetime.25 Yet, as Zika and
poliovirus have been explored
as viral therapies, it would not be
unimaginable to have COVID-19
used as a potential viral therapy

for cancer. Actually, this reality
may not be as far into the future
as one might think. A study shows
that a patient who was diagnosed
with lymphoma actually went
into remission after contracting
COVID-19, highlighting its cancerattacking potential.26
Although some individuals
fear their threat to public health,
the safety of these viruses is
thoroughly tested before they
are even considered as therapies.
Before any testing can be done
on living beings, researchers are
required to provide evidence that
the engineered viruses do not
harm healthy cells. Even with the
safety of these viral constructs
proven, researchers take great care
in keeping the individuals who are
being treated isolated. The patients
are then kept until the virus leaves
their body through waste. The
patient is permitted to come back
for another round of treatment
later on if needed. The lack of
trust in viral constructs prevents
the development of a very safe
and powerful therapy against one
of the deadliest forms of cancer.
Viral cancer therapies represent
a glimmer of hope in a situation
where everything seems to be at its
darkest.
■
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